- Home
- INVE vs ASRT Comparison
INVE vs ASRT Comparison
Compare INVE & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INVE
- ASRT
- Stock Information
- Founded
- INVE 1990
- ASRT 1995
- Country
- INVE United States
- ASRT United States
- Employees
- INVE N/A
- ASRT N/A
- Industry
- INVE Computer peripheral equipment
- ASRT Biotechnology: Pharmaceutical Preparations
- Sector
- INVE Technology
- ASRT Health Care
- Exchange
- INVE Nasdaq
- ASRT Nasdaq
- Market Cap
- INVE 74.2M
- ASRT 57.9M
- IPO Year
- INVE 1997
- ASRT 1997
- Fundamental
- Price
- INVE $3.11
- ASRT $0.65
- Analyst Decision
- INVE Strong Buy
- ASRT Strong Buy
- Analyst Count
- INVE 3
- ASRT 2
- Target Price
- INVE $6.50
- ASRT $3.25
- AVG Volume (30 Days)
- INVE 62.8K
- ASRT 244.4K
- Earning Date
- INVE 08-07-2025
- ASRT 08-06-2025
- Dividend Yield
- INVE N/A
- ASRT N/A
- EPS Growth
- INVE N/A
- ASRT N/A
- EPS
- INVE 3.12
- ASRT N/A
- Revenue
- INVE $25,239,000.00
- ASRT $119,001,000.00
- Revenue This Year
- INVE N/A
- ASRT N/A
- Revenue Next Year
- INVE $9.00
- ASRT $11.91
- P/E Ratio
- INVE $0.99
- ASRT N/A
- Revenue Growth
- INVE N/A
- ASRT N/A
- 52 Week Low
- INVE $2.86
- ASRT $0.51
- 52 Week High
- INVE $4.35
- ASRT $1.80
- Technical
- Relative Strength Index (RSI)
- INVE 50.83
- ASRT 46.76
- Support Level
- INVE $3.08
- ASRT $0.61
- Resistance Level
- INVE $3.28
- ASRT $0.67
- Average True Range (ATR)
- INVE 0.12
- ASRT 0.03
- MACD
- INVE 0.01
- ASRT -0.00
- Stochastic Oscillator
- INVE 53.70
- ASRT 49.12
About INVE Identiv Inc.
Identiv Inc is a security technology company. It secures and manages access to physical places, things, and information. The company has one reportable segment: the IoT Business segment. Geographically, it generates maximum revenue from the Americas and also has a presence in Europe and the Middle East, and Asia-Pacific.
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.